IDEAS home Printed from https://ideas.repec.org/r/aph/ajpbhl/198777111417-1426_6.html
   My bibliography  Save this item

Forecasting coronary heart disease incidence, mortality, and cost: The coronary heart disease policy model

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Davies, Ruth & Roderick, Paul & Raftery, James, 2003. "The evaluation of disease prevention and treatment using simulation models," European Journal of Operational Research, Elsevier, vol. 150(1), pages 53-66, October.
  2. Luz Maria Sánchez-Romero & Joanne Penko & Pamela G Coxson & Alicia Fernández & Antoinette Mason & Andrew E Moran & Leticia Ávila-Burgos & Michelle Odden & Simón Barquera & Kirsten Bibbins-Domingo, 2016. "Projected Impact of Mexico’s Sugar-Sweetened Beverage Tax Policy on Diabetes and Cardiovascular Disease: A Modeling Study," PLOS Medicine, Public Library of Science, vol. 13(11), pages 1-17, November.
  3. K. Cooper & S. Brailsford & R. Davies & J. Raftery, 2006. "A review of health care models for coronary heart disease interventions," Health Care Management Science, Springer, vol. 9(4), pages 311-324, November.
  4. Ankur Pandya & Stephen Sy & Sylvia Cho & Sartaj Alam & Milton C. Weinstein & Thomas A. Gaziano, 2017. "Validation of a Cardiovascular Disease Policy Microsimulation Model Using Both Survival and Receiver Operating Characteristic Curves," Medical Decision Making, , vol. 37(7), pages 802-814, October.
  5. Uwe Siebert, 2003. "When should decision-analytic modeling be used in the economic evaluation of health care?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 4(3), pages 143-150, September.
  6. Tekeshe A Mekonnen & Michelle C Odden & Pamela G Coxson & David Guzman & James Lightwood & Y Claire Wang & Kirsten Bibbins-Domingo, 2013. "Health Benefits of Reducing Sugar-Sweetened Beverage Intake in High Risk Populations of California: Results from the Cardiovascular Disease (CVD) Policy Model," PLOS ONE, Public Library of Science, vol. 8(12), pages 1-9, December.
  7. Peter Lindgren & Bengt Jönsson, 2012. "Cost–effectiveness of statins revisited: lessons learned about the value of innovation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(4), pages 445-450, August.
  8. Magnus Johannesson & Bengt Jönsson & Göran Karlsson, 1996. "Outcome measurement in economic evaluation," Health Economics, John Wiley & Sons, Ltd., vol. 5(4), pages 279-296, July.
  9. Michael F. Drummond;Adrian Towse, 1998. "From Efficacy to Cost-Effectiveness," Briefing 000438, Office of Health Economics.
  10. Gary A. Zarkin & Laura J. Dunlap & Katherine A. Hicks & Daniel Mamo, 2005. "Benefits and costs of methadone treatment: results from a lifetime simulation model," Health Economics, John Wiley & Sons, Ltd., vol. 14(11), pages 1133-1150, November.
  11. Michele Kohli & Cheryl Attard & Annette Lam & Daniel Huse & John Cook & Chantal Bourgault & Evo Alemao & Donald Yin & Michael Marentette, 2006. "Cost Effectiveness of Adding Ezetimibe to Atorvastatin Therapy in Patients Not at Cholesterol Treatment Goal in Canada," PharmacoEconomics, Springer, vol. 24(8), pages 815-830, August.
  12. K Cooper & S C Brailsford & R Davies, 2007. "Choice of modelling technique for evaluating health care interventions," Journal of the Operational Research Society, Palgrave Macmillan;The OR Society, vol. 58(2), pages 168-176, February.
  13. Meltzer, David, 1997. "Accounting for future costs in medical cost-effectiveness analysis," Journal of Health Economics, Elsevier, vol. 16(1), pages 33-64, February.
  14. Rasstrigin, M. & Kitaev, A. & Pleshackova, E., 2023. "Forecasting spending on orphan diseases to maintain the long-run financial sustainability of healthcare system," Journal of the New Economic Association, New Economic Association, vol. 59(2), pages 120-141.
  15. Mark Roberts & Louise B. Russell & A. David Paltiel & Michael Chambers & Phil McEwan & Murray Krahn, 2012. "Conceptualizing a Model," Medical Decision Making, , vol. 32(5), pages 678-689, September.
  16. William S. Weintraub & Samuel S. Gidding, 2016. "PCSK9 Inhibitors: A Technology Worth Paying For?," PharmacoEconomics, Springer, vol. 34(3), pages 217-220, March.
  17. William Weintraub & Samuel Gidding, 2016. "PCSK9 Inhibitors: A Technology Worth Paying For?," PharmacoEconomics, Springer, vol. 34(3), pages 217-220, March.
  18. James E. Smith & Ralph L. Keeney, 2005. "Your Money or Your Life: A Prescriptive Model for Health, Safety, and Consumption Decisions," Management Science, INFORMS, vol. 51(9), pages 1309-1325, September.
  19. Bob J. H. van Kempen & Bart S. Ferket & Albert Hofman & Sandra Spronk & Ewout Steyerberg & M. G. Myriam Hunink, 2012. "Do Different Methods of Modeling Statin Treatment Effectiveness Influence the Optimal Decision?," Medical Decision Making, , vol. 32(3), pages 507-516, May.
  20. Paul Heidenreich & Mark B. McClellan, 2001. "Trends in Heart Attack Treatment and Outcomes, 1975-1995 -- Literature Review and Synthesis," NBER Chapters, in: Medical Care Output and Productivity, pages 363-410, National Bureau of Economic Research, Inc.
  21. Yizhe Xu & Tom H. Greene & Adam P. Bress & Brian C. Sauer & Brandon K. Bellows & Yue Zhang & William S. Weintraub & Andrew E. Moran & Jincheng Shen, 2022. "Estimating the optimal individualized treatment rule from a cost‐effectiveness perspective," Biometrics, The International Biometric Society, vol. 78(1), pages 337-351, March.
  22. Karen T. Hicklin & Julie S. Ivy & James R. Wilson & Fay Cobb Payton & Meera Viswanathan & Evan R. Myers, 2019. "Simulation model of the relationship between cesarean section rates and labor duration," Health Care Management Science, Springer, vol. 22(4), pages 635-657, December.
  23. Marion S. Rauner & Walter J. Gutjahr & Kurt Heidenberger & Joachim Wagner & Joseph Pasia, 2010. "Dynamic Policy Modeling for Chronic Diseases: Metaheuristic-Based Identification of Pareto-Optimal Screening Strategies," Operations Research, INFORMS, vol. 58(5), pages 1269-1286, October.
  24. Amy O’Sullivan & Jaime Rubin & Joshua Nyambose & Andreas Kuznik & David Cohen & David Thompson, 2011. "Cost Estimation of Cardiovascular Disease Events in the US," PharmacoEconomics, Springer, vol. 29(8), pages 693-704, August.
  25. Salkeld, Glenn & Phongsavan, Philayrath & Oldenburg, Brian & Johannesson, Magnus & Convery, Paula & Graham-Clarke, Peita & Walker, Sheila & Shaw, John, 1997. "The cost-effectiveness of a cardiovascular risk reduction program in general practice," Health Policy, Elsevier, vol. 41(2), pages 105-119, August.
  26. Fildes, Robert, 2006. "The forecasting journals and their contribution to forecasting research: Citation analysis and expert opinion," International Journal of Forecasting, Elsevier, vol. 22(3), pages 415-432.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.